Godavari Bioref. Q1 FY27 Earnings Call — Analysis (NSE: GODAVARIB)
Bio-based chemicals delivered strong 19.4% YoY revenue growth and 53% EBITDA surge; commissioning of 200 KLPD grain distillery strengthens integrated biorefinery flexibility.
Result quality: strong — Loss reversed. Management sentiment: optimistic.
The take
Q1FY27 Total Income ₹559.9 Cr ( +4.9% YoY ) . New guidance — FY28 bio-based specialty chemicals q… ₹240 Cr . New story: Bio-chemicals momentum & debottlenecking .
Results
Consolidated revenue ₹557.9 Cr +4.6% YoY; bio-based chemicals revenue ₹168.7 Cr +19.4% YoY, EBITDA ₹19.2 Cr +53%; integrated sugar/ethanol EBITDA loss widened to ₹14.6 Cr; consolidated net loss ₹19.3 Cr vs ₹16 Cr YoY.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue from Operations | ₹557.9 Cr | +4.6% | yoy · Q1FY27 |
| Total Income | ₹559.9 Cr | +4.9% | yoy · Q1FY27 |
| EBITDA | ₹2.6 Cr | yoy · Q1FY27 · Q1 FY26: ₹6.5 Cr | |
| EBITDA Margin | 0.5% | yoy · Q1FY27 · Q1 FY26: 1.2% | |
| Bio-based Chemicals Revenue | ₹168.7 Cr | +19.4% | yoy · Q1FY27 |
| Bio-based Chemicals EBITDA | ₹19.2 Cr | +53% | yoy · Q1FY27 |
| Bio-based Chemicals EBITDA Margin | 11.4% | yoy · Q1FY27 · Q1 FY26: 8.9% | |
| Integrated Sugar/Co-gen/Ethanol Revenue | ₹377.9 Cr | yoy · Q1FY27 · Q1 FY26: ₹382.8 Cr | |
| Integrated Sugar/Co-gen/Ethanol EBITDA | loss ₹14.6 Cr | yoy · Q1FY27 · Q1 FY26: loss ₹4.5 Cr | |
| Net Profit/(Loss) | loss ₹19.3 Cr | yoy · Q1FY27 · Q1 FY26: loss ₹16 Cr | |
| Sugar Inventory (closing) | 65,000 tonnes | point_in_time · Q1FY27 end · as of Q1 FY27 end |
Guidance
Bio-based chemicals Q2 FY27 revenue expected ~₹190 Cr; INR25 Cr debottlenecking capex to be completed by early FY28 targeting ₹240 Cr/quarter; DME pilot results by Mar-27; TNBC efficacy trials expected to commence Q3 FY27.
What management committed to
- Bio-based chemicals revenue for the coming quarter (Q2 FY27) is expected to be approximately ₹190 crore. — ₹190 Cr, Q2FY27
- [Godavari Biorefineries] will invest INR25 crores to further debottleneck [bio-based specialty chemicals] capacity, with completion expected by early FY28. — INR25 Cr, Q1FY28
- After completion of [debottlenecking capex], [bio-based specialty chemicals] business is expected to achieve quarterly revenue of approximately ₹240 crore once full market penetration is achieved. — ₹240 Cr, FY28
- The DME pilot trials will yield final results by March 2027. — Q4FY27
- The triple-negative breast cancer (TNBC) molecule is expected to receive CDSCO permissions and commence preliminary efficacy trials by end of Q3 FY27. — Q3FY27
- [Godavari Biorefineries] will spend approximately INR20 crores over the next 2-3 years to take the [TNBC] drug through preliminary efficacy trials. — INR20 Cr, FY29
Key themes
Bio-chemicals growth, feedstock flexibility, green transition momentum.
How the narrative shifted
- Bio-chemicals momentum & debottlenecking: Management positions bio-based chemicals as the primary growth driver, with strong demand and debottlenecking propelling a step-change in revenue and margins.
- Renewable fuel policy tailwinds: E20 success, draft E85/E100 guidelines, and geopolitical fossil scarcity are accelerating India's green fuel transition.
- Feedstock & product optionality: Multi-feedstock (cane, maize, rice) and flexible product mix (sugar, ethanol, chemicals) give the company operational resilience and ability to capture value across cycles.
- Sugar price recovery potential: Improving sugar realizations may offset recent cost pressures in the integrated sugar-ethanol segment, but outlook remains dependent on policy and climatic conditions.
- Innovation pipeline de-risking: DME, bio-butanol, and oncology drug discovery provide optionality for long-term value creation, with milestones progressively de-risked.
- Capital discipline & quick wins: Capex is focused on high-return debottlenecking that can be funded internally, with no major debt increase or equity raise planned.
Operational commentary
- 200 KLPD grain-based distillery at Sameerwadi commissioned, taking total distillery capacity to 800 KLPD, enhancing feedstock flexibility.
- Evaluating 160 KLPD fungible maize preparation front-end to utilise idle sugarcane fermentation/distillation capacity when diverting more juice to sugar.
- Bio-based chemicals debottlenecking delivering strong results; further INR25 Cr debottlenecking capex approved to raise quarterly revenue run-rate to ~₹240 Cr by early FY28.
- DME pilot trials on track; final results expected by March 2027.
- TNBC anticancer molecule: filed CDSCO application for preliminary efficacy trials; trials expected to start Q3 FY27 subject to approvals.
- Secured Japanese patent for anticancer molecule and Indian patent for branched alcohol process, strengthening IP portfolio.
- Bio-butanol: MoU with Synthomer for chemical intermediate; engaging with government's call for bio-butanol as green fuel.
- Growing customer interest in bio-based chemicals driven by global supply tightness and narrowing fossil-bio price gap.
Analyst Q&A
Q. What is the commercialization roadmap for DME and bio-butanol, and when could they start contributing meaningfully?
DME pilot trials progressing, final results by March 2027; bio-butanol being explored as chemical intermediate (MoU with Synthomer) and as fuel following government's call; market and customer development ongoing.
Q. Should we expect a significantly higher ethanol tender allocation this year than last year's 1,000 LPD?
That question is best asked to the OMC. I may not know the answer to that question.
Q. What is the closing sugar inventory split between long-term contracts and open market?
About 65,000 tons. Long-term contracts may be in the range of 15,000 to 20,000 out of that 65,000, but I'm not exactly sure.
Research and educational content only. Not investment advice.